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Urine lipoarabinomannan testing in children with tuberculosis
An estimated 1 million (999 792; 95% CI 
937 877–1 055 414) children develop tuberculosis every 
year; most cases arise in southeast Asia (397 040; 
350 615–447 474), Africa (279 825; 250 187–308 717), 
and the western Paciﬁ c (179 515; 159 246–202 626).1 
Tuberculosis is probably a major unrecognised cause 
of under-5 mortality in tuberculosis-endemic areas, 
especially in children dying from pneumonia, meningitis, 
sepsis, HIV/AIDS, and severe malnutrition.2 Autopsy 
studies from ﬁ ve African countries identiﬁ ed tuberculosis 
in roughly 10% of 811 children (both HIV-positive and 
HIV-negative) who died from presumed pneumonia.3 
This ﬁ nding provides a sad reminder of the diagnostic 
challenges in resource-limited settings, which restrict 
children’s access to tuberculosis treatment that is cheap, 
eﬀ ective, and well tolerated.
The holy grail of tuberculosis diagnostics is a 
rapid and reliable point-of-care test that is able to 
diﬀ erentiate latent infection from active disease 
and can be done on a readily available specimen.4,5 
The tuberculin skin test provides information about 
likely Mycobacterium tuberculosis infection, but fails to 
identify active disease. Interferon-gamma release assays 
(eg, QuantiFERON-Gold In Tube [Cellestis, Carnegie, 
VIC, Australia] and T-Spot.TB [Oxford Immunotec, 
Oxford, UK]) provide improved speciﬁ city compared 
with the tuberculin skin test, but also fail to make the 
crucial distinction between latent infection and active 
disease.6,7 Although these tests are helpful to identify 
M tuberculosis infection in asymptomatic children 
during immigrant screening or contact investigation, 
their utility is restricted in tuberculosis-endemic settings 
where M tuberculosis infection is ubiquitous.7 Sputum 
smear microscopy, the traditional cornerstone of 
tuberculosis diagnosis, has no value in young children 
who are unable to expectorate. Induced sputum and 
gastric or nasopharyngeal aspirates provide alternative 
respiratory specimens,8 but specimen collection is 
cumbersome and the bacteriological yield is low, even 
with the use of liquid culture or Xpert MTB/RIF.9,10
In this issue of The Lancet Global Health, Mark Nicol 
and colleagues11 report the diagnostic accuracy of two 
commercially available rapid urine tests to identify active 
tuberculosis in children. Lipoarabinomannan is a unique 
component of the mycobacterial cell wall that is excreted 
in the urine of some patients with tuberculosis. Findings 
of studies to assess the diagnostic ability of urine 
lipoarabinomannan assays in adults suspected of having 
tuberculosis showed poor sensitivity but good speciﬁ city.12 
Test utility was greatly improved when the assay was used 
in combination with other tests to screen HIV-positive 
patients for tuberculosis before initiation of antiretroviral 
therapy; sensitivity increased in severely immune-
compromised individuals and speciﬁ city remained high.13 
These ﬁ ndings provided the rationale to assess the 
value of urinary lipoarabinomannan assays in children 
suspected of having tuberculosis because the collection of 
respiratory specimens is arduous in young children who 
are unable to expectorate, and occult haematogenous 
dissemination associated with primary infection might 
increase urinary lipoarabinomannan excretion.
The present study included 535 children (median 
age 42·5 months) with suspected tuberculosis in 
whom urine and two induced sputum specimens were 
collected. Investigators collected urine specimens in 
urinary bags attached to the child’s perineum and frozen 
at –80°C. Both a lateral ﬂ ow assay and ELISA assay 
(Clearview, Alere, Waltham, USA) were done on batched 
unfrozen specimens. Urinary lipoarabinomannan assays 
did not diﬀ erentiate the 89 children with culture-
conﬁ rmed tuberculosis from those with possible 
tuberculosis (n=250) or no tuberculosis (n=196). Poor 
sensitivity (48·3% lateral ﬂ ow assay; 2·2% Clearview) 
might have been expected in view of previous results 
in adults and the use of a reference standard based on 
respiratory specimens. However, the poor speciﬁ city 
(60·8% with lateral ﬂ ow assay) and highly discrepant 
results reported with the various tests were unexpected. 
Less than 50% of specimens that tested positive (with 
a maximum 5 band intensity readout) on lateral ﬂ ow 
assay tested positive with ELISA.
These disappointing results might be indicative of 
the paucibacillary nature of paediatric tuberculosis with 
minimum lipoarabinomannan excretion in the urine. 
However, the fact that tests also did poorly in children 
with disseminated (miliary) tuberculosis makes this 
explanation unlikely. Other considerations include 
the possible eﬀ ect of prolonged freezing of the urine 
specimens before testing, poor laboratory technique, or 
manufacturing errors. None of these explanations seem 
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likely because the laboratory is highly experienced and 
followed the exact same protocol used in previous adult 
trials, and repeated assays that used kits with diﬀ erent 
batch numbers achieved similar results. The most 
plausible explanation for the poor speciﬁ city and poor 
intertest reliability might be related to the use of urine 
bags for specimen collection. Urine bags are attached to 
the perineum and are often left in situ for hours, with high 
rates of bacterial contamination and overgrowth. This 
method might account for the variable results achieved 
in the present study, whereas more reliable results were 
achieved in adult studies by use of clean-catch specimens.
Although assessment of the potential eﬀ ect of bacterial 
overgrowth on urine lipoarabinomannan tests might be 
of interest, no evidence exists that urine-based antigen 
or genetic14 tests have clinical application in children 
suspected of having tuberculosis. Further exploration of 
the utility of urinary lipoarabinomannan tests in children 
with possible disseminated (miliary) tuberculosis, in 
whom a rapid diagnosis is of paramount importance, 
seems warranted if urine collection can be optimised. In 
the meantime, the search for a reliable point-of-care test 
continues.
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